![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/c47de2e4c3a914fe4fc4fc05c2c1f849434885ff-3200x2133.jpg?fit=crop&auto=format)
Phase 3 Trial Highlights Efficacy of Dupilumab for EoE in Children Aged 1 to 11
Children aged 1 to 11 years with eosinophilic esophagitis (EoE) receiving weight-tiered higher dose dupilumab (Dupixent; Sanofi) demonstrated significant improvements in symptoms compared with placebo in a phase 3 trial (NCT04394351). The results indicated …